| Janssen-Cilag AG - Darzalex 400mg/20ml, Konzentrat zur Herstellung einer Infusionslösung |
| 66072 | | 04 | | Darzalex 400mg/20ml | | Konzentrat zur Herstellung einer Infusionslösung | | L01FC01 | | | | 27.01.2023 | | |
|
| Composition |
| daratumumabum 400 mg, histidinum, histidini hydrochloridum monohydricum, sorbitolum 1093.0 mg, methioninum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 5 ml. |
| Packungsbestandteile |
| Concentrate for infusion | | | | | | | | Active Agent | Dose |
|---|
| Daratumumabum | 400mg / 5ml |
| | BAG: Active Agent | Dose |
|---|
| Daratumumabum | 400 mg |
| | | | Inactive agents | Dose |
|---|
| Histidin Hydrochloride Monohydrate | | | Histidine | | | Methionine | | | Polysorbatum 20 | | | Sorbitol | 1093mg / 5ml |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 004 | | 1609.68 | 1767.05 | A | SL | No |
|
